Loading...
DOCUMENTS
20
NOTICES
33
MOTS CLES
Inflammatory bowel diseases
Disability
Résistance
Therapeutics
Gene expression
Bacteria
Helicobacter pylori
Ulcerative colitis
IL12
Surgery
DNA methylation
MALT
Crohn’s disease
Inflammatory Bowel Diseases
Colonic epithelial primary cells
Tailored therapy
Eligibility
Survival
Microbiota
HIV
Anti-TNF
Biologics
IL23
Colorectal cancer
Biomarker
Eradication
Crohn's disease
Endoscopic treatment
Alkylating agents
Immune cells
IBD
18 FDG-PET/CT
Rituximab plus chlorambucil
Monitoring
Clinical guidelines
Patients experience
Over 80s
Drug
Colectomy
Neoadjuvant chemotherapy
Epigenetics
Methylation
Venous thromboembolism
Resistance
CARCINOGENESIS
Thérapie ciblée
Maintenance therapy
MORTALITY
Colon
Colorectal cancer Colibactin and lipids
Inflammatory bowel disease
Safety
Epigénétiques
Contraindication
Microbiote
Clinical trial
Gene methylation
Disease Progression
Colon cancer
Upper gastrointestinal tract
Rituximab
Kidney diseases
Stricture
Inclusion
Original Article Clinical
Bactéries
Tuberculosis
Cost effectiveness
Fecal microbiota
Cell adhesion
PCR
Parvimonas micra
MICROBIOTA
Immunosuppressant
Small molecules
Disease progression
Screening
Genes
Intestinal crypts
Acceptability
Dysbiosis
Effectiveness
Vedolizumab
DNA METHYLATION
Inhibitor
COLON-CANCER
Algorithm
Heart disease risk factors
MARKER
Patient-reported outcome
Anti-TNF agents
Cancer
Ustekinumab
Dysbiose
T1118 translocation
Consensus
Gènes
RISK
Méthylation
Primary sclerosing cholangitis
Early detection of Colon Cancer using Molecular Markers and Microbiota , EA 7375 | |
---|---|
Institutions |
UPEC |
Adresse |
Université Paris-Est Créteil Groupe Hospitalier Henri Mondor Service de Gastroentérologie 51 Av Maréchal de Lattre de Tassigny 94010 Créteil cedex |
Courriel |
|
Site Internet |
|
Rattachement(s) |
|
Direction |
Aurélien AMIOT |
Adjoint |
Iradj SOBHANI |
Axe(s) de recherche
|
Le laboratoire axe ses recherches sur le rôle du microbiome intestinal ainsi que des changements épigénétiques dans l'intestin afin :
|